secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-06-29T11:20:20+00:00
Accession:  0001193125-26-286829
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks to acquire Theravance Biopharma for $17/share (~$929M total cash consideration)
--------------------------------------------------------------------------------

- Deal adds YUPELRI (revefenacin) with ~$60M annualized cash flow from 35% U.S. profit share
- Financing: $350M non-recourse note from OMERS Life Sciences, plus Zymeworks cash and Theravance's ~$360M net cash at close
- Shareholders receive $17 cash plus one CVR per share tied to ampreloxetine monetization (80% of net proceeds to CVR holders)
- Zymeworks expects $100M Trelegy milestone from Royalty Pharma in Q1 2027; also retains ~$2.5B Irish tax attributes
- Transaction expected to close in H2 2026; Zymeworks also maintains up to $125M share repurchase program

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/0001193125-26-286829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/d156494d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer